After the most recent ESC guidelines and findings about the usefulness of SGLT2 inhibitors in HFpEF patients, the use of SGLT2 inhibitors in patients with heart failure needs to be further investigated in order to optimize the setting of their administration [67]. Here, SLC5A2 is linked to heart failure.